Figure 1.The VirusExpress® Production Platform features a suspension adapted cell line, chemically defined medium, and production process with proven performance.
The VirusExpress® Production Platform offers a transfection-based solution to lentivirus (LV) or adeno-associated virus (AAV) production challenges, featuring a suspension adapted cell line, chemically defined medium, and production process with proven performance at up to 50 L scale.
With a platform that can dramatically reduce the time in process development and scale-up, whether performed in your facilities or leveraging our gene therapy CDMO capabilities, you can draw on our experience to speed your gene therapy to patients.
For performance data on VirusExpress® 293 AAV Production Platform, click here.
Cell viability (dashed lined) and cell growth data (solid lines)
Each run exceeded a target functional titer of 1 x 107 TU/mL and demonstrated successful scale-up to 40 L
VirusExpress® Production Platform Specifications